Technical Analysis for BNOX - Bionomics Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.74% | |
| Wide Bands | Range Expansion | 0.74% | |
| Crossed Above 20 DMA | Bullish | -4.34% | |
| Outside Day | Range Expansion | -4.34% | |
| Wide Bands | Range Expansion | -4.34% | |
| 20 DMA Resistance | Bearish | -1.39% | |
| NR7 | Range Contraction | -1.39% | |
| NR7-2 | Range Contraction | -1.39% | |
| Narrow Range Bar | Range Contraction | -1.39% | |
| Wide Bands | Range Expansion | -1.39% |
| Alert | Time |
|---|---|
| Down 3% | about 2 hours ago |
| Down 2 % | about 2 hours ago |
| Down 1% | about 2 hours ago |
| 60 Minute Opening Range Breakdown | about 2 hours ago |
| Rose Above 20 DMA | about 3 hours ago |
Get a Trading Sidekick!
- Earnings date: 04/29/2024
Bionomics Limited Description
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Drugs Cancer Treatment Alzheimer's Disease Monoclonal Antibodies Stem Cell Antineoplastic Drugs Central Nervous System Disorders Post Traumatic Stress Disorder Cognitive Impairment Treatment Of Central Nervous System Disorders Camidanlumab Tesirine Anxiolytics Milatuzumab
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.95 |
| 52 Week Low | 0.177 |
| Average Volume | 11,889,124 |
| 200-Day Moving Average | 0.75 |
| 50-Day Moving Average | 0.38 |
| 20-Day Moving Average | 0.29 |
| 10-Day Moving Average | 0.32 |
| Average True Range | 0.07 |
| RSI (14) | 46.52 |
| ADX | 21.85 |
| +DI | 27.23 |
| -DI | 24.34 |
| Chandelier Exit (Long, 3 ATRs) | 0.40 |
| Chandelier Exit (Short, 3 ATRs) | 0.40 |
| Upper Bollinger Bands | 0.45 |
| Lower Bollinger Band | 0.13 |
| Percent B (%b) | 0.47 |
| BandWidth | 109.81 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.02 |
| MACD Histogram | 0.0044 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.37 | ||||
| Resistance 3 (R3) | 0.37 | 0.35 | 0.35 | ||
| Resistance 2 (R2) | 0.35 | 0.33 | 0.35 | 0.35 | |
| Resistance 1 (R1) | 0.32 | 0.31 | 0.30 | 0.31 | 0.34 |
| Pivot Point | 0.29 | 0.29 | 0.29 | 0.29 | 0.29 |
| Support 1 (S1) | 0.26 | 0.27 | 0.25 | 0.25 | 0.22 |
| Support 2 (S2) | 0.24 | 0.26 | 0.24 | 0.22 | |
| Support 3 (S3) | 0.20 | 0.24 | 0.21 | ||
| Support 4 (S4) | 0.20 |
